Human pluripotent stem cell-derived insulin-producing cells: A regenerative medicine perspective.

Human pluripotent stem cell-derived insulin-producing cells: A regenerative medicine perspective.
复制标题

DOI:
10.1016/j.cmet.2021.03.021
复制
发表时间:
2021-04-06
期刊:
影响因子:
29
通讯作者:
Sneddon JB
Sneddon JB
中科院分区:
生物学1区
文献类型:
--
作者:
Migliorini A;Nostro MC;Sneddon JB

文献摘要

参考文献

被引文献

相似文献

在过去的二十年中,β细胞替代疗法作为一种治疗糖尿病的方法已经取得了巨大的进展。移植研究已经证明了治疗效果,cGMP级细胞产品目前正在首次用于人体临床试验。从这个角度来看,我们讨论了当前干细胞衍生的胰岛样细胞的产生、传递和移植所面临的挑战,以及诱导对移植细胞持久耐受性的策略,并着眼于一种功能性细胞治疗,使糖尿病患者能够独立于胰岛素。
Tremendous progress has been made over the last two decades in the field of beta cell replacement therapy as a curative measure for diabetes. Transplantation studies have demonstrated therapeutic efficacy, and cGMP grade cell products are currently being deployed for first in human clinical trials. In this perspective, we discuss current challenges surrounding the generation, delivery, and engraftment of stem cell-derived islet-like cells, along with strategies to induce durable tolerance to grafted cells, with an eye towards a functional cellular-based therapy enabling insulin independence for patients with diabetes.
DOI: 10.1126/scitranslmed.aae0501
发表时间: 2016-08-10
影响因子: 17.1
作者:
Chhabra A;Ring AM;Weiskopf K;Schnorr PJ;Gordon S;Le AC;Kwon HS;Ring NG;Volkmer J;Ho PY;Tseng S;Weissman IL;Shizuru JA
通讯作者: Shizuru JA
DOI: 10.1007/s00125-020-05345-8
发表时间: 2021-03
期刊: Diabetologia
影响因子: 8.2
作者:
Cottle L;Gan WJ;Gilroy I;Samra JS;Gill AJ;Loudovaris T;Thomas HE;Hawthorne WJ;Kebede MA;Thorn P
通讯作者: Thorn P
DOI: 10.2337/diabetes.45.9.1161
发表时间: 1996-09-01
期刊: DIABETES
影响因子: 7.7
作者:
Davalli, AM;Scaglia, L;Weir, GC
通讯作者: Weir, GC
DOI: 10.1111/ajt.12872
发表时间: 2014-11-01
影响因子: 8.8
作者:
Balamurugan, A. N.;Naziruddin, B.;Barton, F. B.
通讯作者: Barton, F. B.
DOI: 10.1038/nbt.4114
发表时间: 2018-04-01
影响因子: 46.9
作者:
da Cruz, Lyndon;Fynes, Kate;Coffey, Peter J.
通讯作者: Coffey, Peter J.